1. Academic Validation
  2. CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation

CXCR3 antagonist AMG487 ameliorates experimental autoimmune prostatitis by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation

  • Prostate. 2022 Sep;82(13):1223-1236. doi: 10.1002/pros.24395.
Xiaoliang Hua 1 2 3 Jiong Zhang 1 2 3 Shengdong Ge 1 2 3 Haoran Liu 1 2 3 Hexi Du 3 Qingsong Niu 1 3 Xianguo Chen 1 2 3 Cheng Yang 1 2 3 Li Zhang 1 2 3 Chaozhao Liang 1 2 3 4
Affiliations

Affiliations

  • 1 Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
  • 2 Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China.
  • 3 The Institute of Urology, Anhui Medical University, Hefei, China.
  • 4 Anhui Institute of Translational Medicine, Hefei, China.
Abstract

Background: Chronic prostatitis and chronic pelvic pain syndrome (CP/CPPS) is an inflammatory immune disease that is characterized by infiltrating inflammatory cells in the prostate and pelvic or by perineal pain. Receptor CXCR3modulates immune and inflammatory responses; however, the effects of CXCR3 Antagonist AMG487 in the context of CP/CPPS are unknown. Therefore, we investigated the effect of AMG487 in experimental autoimmune prostatitis (EAP) mice and explored the potential functional mechanisms.

Methods: The EAP model was induced by intradermally injecting a mixture of prostate antigens and complete Freund's adjuvant on Days 0 and 28. To evaluate the effect of AMG487 on EAP mice, treatment with AMG487 and vehicle solution was conducted for the indicated period. Then, procedures were performed, including behavioral test, to evaluate the pain response to stimulation before the mice were killed and a histological assessment to evaluate the inflammation after the mice were killed. Immunofluorescence, flow cytometry, and Western blot assay were used to analyze the functional phenotype and regulation mechanism of AMG487 on T helper type 1 (Th1) cells and macrophages.

Results: We found high expression of CXCR3 in human benign prostate tissues with inflammation and EAP mice. The elevated CXCR3 in prostate tissues correlates with the severity of inflammation. CXCR3 Antagonist AMG487 treatment ameliorated the inflammatory changes and the pelvic pain of EAP mice. AMG487 inhibits Th1 cell differentiation through the IL-12/STAT4pathway and inhibits pro-inflammatory M1 macrophages through the lipopolysaccharide/NF-κB p65signaling. AMG487 could inhibit the secretion of inflammatory mediators in EAP mice.

Conclusion: CXCR3 Antagonist AMG487 could ameliorate the inflammatory changes and the pelvic pain of EAP mice by diminishing Th1 cell differentiation and inhibiting macrophage M1 phenotypic activation. Thus, the results imply that AMG487 has the potential as an effective therapeutic agent in the prevention and treatment of EAP.

Keywords

AMG487; CXCR3; chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS); immune; inflammation.

Figures
Products